暴跌70%，中国医美巨头神话破灭

Core Viewpoint - Langzi Co., Ltd. is facing a dual dilemma of growth slowdown and profit pressure, with its market value plummeting over 70% from a peak of over 30 billion to 8.2 billion [1][26]. Group 1: Company Background and Business Structure - Founded in 2000, Langzi initially focused on high-end women's clothing and later expanded into the mother and baby, medical beauty, and internet sectors through acquisitions and investments [13][14]. - The company has three core business segments: women's clothing, medical beauty, and baby products, with a significant shift in market focus towards medical beauty since 2016 [13][14]. Group 2: Recent Stock Reduction Activities - On June 9, 2023, Langzi announced a plan to reduce its stake in Ruoyuchen by up to 4.7681 million shares, representing no more than 3% of the total share capital [1][3]. - The stock reduction comes at a time when Ruoyuchen's stock price has surged by 610% over the past year, indicating a strategic move to capitalize on high stock prices [1][3][10]. Group 3: Financial Performance and Challenges - Langzi's asset-liability ratio has increased significantly from 10.48% in 2011 to a historical high of 57.42% in 2024, indicating rising financial pressure [16][18]. - Despite high gross margins (around 59% in 2024), the net profit margin has drastically declined to 5.19%, highlighting the challenges in profitability within the medical beauty sector [20][21]. - The company has incurred substantial sales expenses, totaling 119 billion from 2017 to 2024, which represents approximately 39% of total revenue during that period [22][23]. Group 4: Market Trends and Future Outlook - The medical beauty industry is experiencing a decline in average customer spending, with reports indicating a nearly 40% drop in per capita spending, which could further impact Langzi's revenue [27]. - The company's goodwill has reached 1.781 billion, accounting for 64% of its net assets, posing a risk of impairment if acquired entities underperform [24][25].